Structural Heart

This structural heart channel includes news, videos, podcasts and other content related to diagnosis and treatment of structural heart disease. Topics covered include heart valve repair and replacement, transcatheter aortic valve replacement (TAVR), transcatheter mitral valve replacement (TMVR), transcatheter tricuspid valve replacement (TTVR), left atrial appendage (LAA) occlusion, heart failure interventional device therapies, and closing holes in the heart using, including occlusion of atrial septal defects (ASDs), ventricular septal defects (VSDs) and patent foramen ovales (PFOs).

A 3-D reconstruction of a cardiac CT scan showing an implanted Medtronic CoreValve TAVR device. Imagine courtesy of TeraRecon. #TAVR #TAVI

A 3-D reconstruction of a cardiac CT scan showing an implanted Medtronic CoreValve TAVR device. Image courtesy of TeraRecon

Feature | Heart Valve Technology | February 24, 2020 | Dave Fornell, Editor
In August 2019, the U.S. Food and Drug Administration (FDA) expanded the indication for the use of transcatheter aortic...
Videos | Heart Valve Technology | February 18, 2020
Andrew Weintraub, M.D., FACC, associate director, of the Interventional Cardiology and Vascular Center, medical...
The U.S. Food and Drug Administration (FDA) has approved a the CATALYST trial designed to assess Abbott's Amplatzer Amulet left atrial appendage (LAA) occluder for people with atrial fibrillation (AF or AFib). 
News | Left Atrial Appendage (LAA) Occluders | February 03, 2020
February 3, 2020 — The U.S. Food and Drug Administration (FDA) has approved a the CATALYST trial designed to assess...
The Abbott Tendyne transcatheter mitral valve replacement (TMVR) system, left, became the first TMVR device to gain commercial regulatory clearance in the world. It gains European CE mark in January. Another top story in January was the first use of the Robocath R-One robotic cath lab catheter guidance system in Germany.  Watch a VIDEO of the system in use in one of those cases. 

The Abbott Tendyne transcatheter mitral valve replacement (TMVR) system, left, became the first TMVR device to gain commercial regulatory clearance in the world. It gains European CE mark in January. Another top story in January was the first use of the Robocath R-One robotic cath lab catheter guidance system in Germany.  Watch a VIDEO of the system in use in one of those cases. 

News | February 03, 2020 | Dave Fornell, Editor
February 3, 2020 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC)...
Raj Makkar, M.D., led a multicenter national study comparing outcomes for minimally invasive heart valve replacement to open-heart surgery. Photo by Cedars-Sinai. TAVR performs as well as surgery for aortic valve replacement.

Raj Makkar, M.D., led a multicenter national study comparing outcomes for minimally invasive TAVR heart valve replacement to open-heart surgery. The study showed the two methods have similar outcomes. Photo by Cedars-Sinai.

News | Heart Valve Technology | January 31, 2020
January 31, 2020 — A new study from the Smidt Heart Institute at Cedars-Sinai and other centers nationwide shows that...
Abbott Tendyne TMVR, TMVI system received European CE mark clearance in January 2020. The Abbott Tendyne transcatheter mitral valve replacement (TMVR) system uses an anchor attached to the apex of the heart with a whether line attached to the valve. This helps to keep the valve anchored in the mitral annulus and prevent embolization. This anchor system was used because, unlike the aortic valve, the mitral valve has a very thin landing zone to secure the valve. Prevents LVOT obstruction.

The Abbott Tendyne transcatheter mitral valve replacement (TMVR) system uses an anchor attached to the apex of the heart with a whether line attached to the valve. This helps to keep the valve anchored in the mitral annulus and prevent embolization. This anchor system was used because, unlike the aortic valve, the mitral valve has a very thin landing zone to secure the valve. The design also eliminated any hardware hanging or folding into the left ventricle, which could cause left ventricular outflow track (LVOT) obstruction, which can prevent blood flow through the aortic valve and to the rest of the body.

Feature | Heart Valve Technology | January 30, 2020
January 30, 2020 — The Abbott Tendyne Transcatheter Mitral Valve Implantation (TMVI) system received European CE mark...
Videos | Heart Valve Technology | January 28, 2020
Interview with Andrew Weintraub, M.D., FACC, associate director, of the Interventional Cardiology and Vascular Center,...
This is an example of artificial intelligence automation for cardiac MRI using an AI app from TeraRecon's Envoy AI marketplace. The GE MRI image has bee countoured, anatomy labeled and all quantification automated by the AI, greatly reducing post-processing time. See this and other new AI imaging technologies from the 2019 RSNA meeting.

This is an example of artificial intelligence automation for cardiac MRI using an AI app from TeraRecon's Envoy AI marketplace. The GE MRI image has been countoured, anatomy labeled and all quantification automated by the AI, greatly reducing post-processing time. See this and other new AI imaging technologies from the 2019 RSNA meeting.

Blog | January 24, 2020
The key question I am always asked at cardiology conferences is what are the trends and interesting new technologies I...
The BioVentrix Revivent TC transcatheter device anchors that help cinch the heart mucsle using a transcatheter procedure to treat left ventricular remodeling associated with heart failure following a heart attack. BioVentrix Inc., developer of the first transcatheter device for left ventricular remodeling after a heart attack, announced the extension of its European CE mark approval for the Revivent TC Transcatheter Ventricular Enhancement System for heart failure to May 2024.

The BioVentrix Revivent TC transcatheter device anchors that help cinch the heart mucsle using a transcatheter procedure to treat left ventricular remodeling associated with heart failure following a heart attack.

News | January 22, 2020
January 22, 2020 – BioVentrix Inc., developer of the first transcatheter device for left ventricular remodeling after a...
Mayo Clinic uses the Da Vinci surgical robot to perform minimally invasive mitral valve surgeries.
News | Robotic Systems | January 20, 2020
January 20, 2020 — Research has found that repairing the mitral valve earlier, before the mitral valve prolapse...
This is the latest version of the MitraClip, the G4, which allows each side of the clip to be opened and closed independently to offer more flexibility when capturing the valve leaflets. The device is being used in the REPAIR MR clinical trial.

This is the latest version of the MitraClip, the G4, which allows each side of the clip to be opened and closed independently to offer more flexibility when capturing the valve leaflets. The device is being used in the REPAIR MR clinical trial. 

News | Heart Valve Technology | January 13, 2020
January 13, 2020 — The U.S. Food and Drug Administration (FDA) has approved clinical trial that will compare the...
This photo is from a MitraClip procedure during the University of Colorado visit last December.

Ten out of the top 25 videos in 2019 are from hospital site visits DAIC conducted and shot more than 10 video interviews and recorded cath lab procedures at each center.  Two of the videos here are walk throughs of cath labs, showing how Henry Ford Hospital and the University of Colorado set up their main hybrid rooms for structural heart procedures. This photo is from a MitraClip procedure during the University of Colorado visit last December.

Feature | December 30, 2019 | Dave Fornell, Editor
Here are the top performing 25 videos posted to the DAIC website in the past year, based on Google Analytics. These the...
The Wyss Translational Center in Zurich, Switzerland has developed the LifeMatrix platform to engineer tissues that can be implanted in patients and will grow with them. This technology is being developed for heart valves in younger patients to eliminate the need for repeat surgeries to implant larger prosthetic heart valves as the patient grows.

The Wyss Translational Center in Zurich, Switzerland has developed the LifeMatrix platform to engineer tissues that can be implanted in patients and will grow with them. This technology is being developed for heart valves in younger patients to eliminate the need for repeat surgeries to implant larger prosthetic heart valves as the patient grows.

 

News | Heart Valve Technology | December 26, 2019
While transcatheter heart valve replacement and repair devices are growing in popularity due to their delivery and...
Append Medical, developer of a novel left atrial appendage (LAA) closure device to minimize stroke risk in atrial fibrillation (AF) patients, announced that it has been selected from among hundreds of startups as a finalist for the ICI Innovation Award Competition. It uses a transcatheter lasso system so no implant is left behind and eliminates the possibility of embolization.

Append Medical, developer of a novel left atrial appendage (LAA) closure device to minimize stroke risk in atrial fibrillation (AF) patients, announced that it has been selected from among hundreds of startups as a finalist for the ICI Innovation Award Competition. It uses a transcatheter lasso system so no implant is left behind and eliminates the possibility of embolization.

News | Left Atrial Appendage (LAA) Occluders | December 18, 2019
December 18, 2019 — Append Medical, developer of a novel left atrial appendage (LAA) closure device to minimize stroke...
 Revivant TC
News | Heart Failure | December 18, 2019
December 18, 2019 — BioVentrix, Inc., developer of the first less invasive system for left ventricular remodeling,...